Switch to infliximab biosimilar ticks all boxes

Switching patients with IBD from infliximab to a biosimilar is safe and non‐inferior to continuing treatment with originator infliximab, Australian research shows. The reassuring findings come from an observational study led by Dr Craig Heifer of St Vincent’s Hospital, Sydney, in which four hospitals switched 202 adults from infliximab to the biosimilar CT-P13 (Inflectra) and ...

Already a member?

Login to keep reading.

© 2021 the limbic